Form 4: NewAmsterdam Pharma Co N.V. Executive Douglas Kling Reports Share Sales
SEC Form 4 Filing
Douglas Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., reported the sale of ordinary shares on January 29th and 30th, 2025, alongside the exercise of options to acquire shares.
Summary
- Douglas Kling, the Chief Operating Officer of NewAmsterdam Pharma Co N.V., filed a Form 4 detailing changes in beneficial ownership.
- On January 29, 2025, Kling exercised options to acquire 56,863 ordinary shares and sold the same amount.
- On January 30, 2025, Kling exercised options to acquire 13,578 ordinary shares and sold 4,664 shares and 8,914 shares in two separate transactions.
- The sales were executed under a pre-arranged trading plan in accordance with Rule 10b5-1.
- The option exercise price is 1.16392 euros.
- Following these transactions, Kling directly owns 44,000 ordinary shares.
- Kling also holds options to buy 226,145 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a routine filing related to executive stock transactions. It doesn't contain any information that would significantly impact the company's outlook or investor sentiment.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. They can be driven by various factors, including personal financial planning and diversification. It's important to consider the context of these sales, such as whether they are part of a pre-planned trading program and the overall trading activity of other insiders.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- Rule 10b5-1 trading plans are a common mechanism for insiders to sell shares without being accused of trading on non-public information.
- The volume of shares sold by Kling is relatively small compared to the total outstanding shares of NewAmsterdam Pharma Co N.V.
Key Dates
| Date | Description |
|---|---|
| 07/06/2021 | Original grant date of option that was later cancelled. |
| 11/22/2022 | Option granted to replace the option originally granted on July 6, 2021. |
| 01/29/2025 | Exercise of options and sale of 56,863 ordinary shares. |
| 01/30/2025 | Exercise of options and sale of 13,578 ordinary shares. |
| 01/31/2025 | Date of Form 4 filing. |
| 07/06/2031 | Expiration date of options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.